Yanghui Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanghui Hu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bijun Xu
The First Dongguan Affiliated Hospital, Guangdong Medical University
1 shared publication - Chun Yang
Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, The First Dongguan Affiliated Hospital, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, China
1 shared publication - Jinfeng Zhu
The First Dongguan Affiliated Hospital, Guangdong Medical University
1 shared publication - Mengting Zhang
Department of Second Clinical Medical School, Guangdong Medical University, Dongguan, China
1 shared publication - Mianda Hu
The First Dongguan Affiliated Hospital, Guangdong Medical University
1 shared publication - Weichui Zhang
The First Dongguan Affiliated Hospital, Guangdong Medical University
1 shared publication
Latest Publications
- 9 May 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (2) , 201-211
A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen
Ibuprofen is commonly used as an over-the-counter (OTC) antipyretic and analgesic. As the frequency of its use increases, there has been a corresponding increase in reports of associated adverse events (AEs). However, these events have not been systematically reported in the literature. Meanwhile, the importance of effective pharmacovigilance in evaluating the benefits and risks of drugs is being recognized. Data were obtained indirectly from FAERS using the OpenVigil 2 database, lexically mapped using software such as MySQL, Microsoft Excel, and the R language, and then subjected to four more rigorous algorithms to detect risk signals associated with ibuprofen AEs. By analyzing data from the past 18 years, 878 ibuprofen-related AEs were identified as primary AEs. Notably, unexpected reproductive system and breast disorders were observed as important system organ classes (SOC) associated with ibuprofen. Among the 651 preferred terms (PTs) that simultaneously satisfied the four arithmetic methods, we propose renal tubular acidosis and lip edema as new signals for AEs of ibuprofen. The study explores the important and valuable potential AEs and ADRs of ibuprofen at the SOC and PT levels, respectively. To provide a reference for decision-making for ibuprofen to promote rational clinical dosing.
- 9 May 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (2) , 201-211
A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen
Ibuprofen is commonly used as an over-the-counter (OTC) antipyretic and analgesic. As the frequency of its use increases, there has been a corresponding increase in reports of associated adverse events (AEs). However, these events have not been systematically reported in the literature. Meanwhile, the importance of effective pharmacovigilance in evaluating the benefits and risks of drugs is being recognized. Data were obtained indirectly from FAERS using the OpenVigil 2 database, lexically mapped using software such as MySQL, Microsoft Excel, and the R language, and then subjected to four more rigorous algorithms to detect risk signals associated with ibuprofen AEs. By analyzing data from the past 18 years, 878 ibuprofen-related AEs were identified as primary AEs. Notably, unexpected reproductive system and breast disorders were observed as important system organ classes (SOC) associated with ibuprofen. Among the 651 preferred terms (PTs) that simultaneously satisfied the four arithmetic methods, we propose renal tubular acidosis and lip edema as new signals for AEs of ibuprofen. The study explores the important and valuable potential AEs and ADRs of ibuprofen at the SOC and PT levels, respectively. To provide a reference for decision-making for ibuprofen to promote rational clinical dosing.